Rapport Therapeutics Reports 77.8% Seizure Reduction, Eyes Phase 3 in Q2 2026
RAPP’s lead candidate RAP-219 delivered a median 77.8% reduction in seizure frequency and 24% seizure freedom in a 30-patient Phase 2a focal onset seizure trial, supporting a >$2B U.S. market opportunity. The company ended 2025 with $490.5M cash and will start Phase 3 FOS studies in Q2 2026.
1. Financial Results and Cash Runway
The company reported cash, cash equivalents and short-term investments of $490.5 million at year-end, a balance strengthened by a follow-on common stock offering that is expected to fund operations into the second half of 2029.
2. Robust Phase 2a Focal Onset Seizure Data
In a 30-patient Phase 2a trial of RAP-219 in drug-resistant focal onset seizures, patients achieved a median 77.8% reduction in clinical seizure frequency (p=0.01), with 72% attaining ≥50% reduction and 24% achieving seizure freedom over eight weeks, demonstrating early onset and sustained benefit across baseline severities.
3. Accelerated Phase 3 and Pipeline Expansion
Following an end-of-Phase 2 FDA meeting, the company moved up the start of its pivotal Phase 3 FOS program to Q2 2026, initiated enrollment in an open-label long-term safety trial, and plans to launch a Phase 3 program in primary generalized tonic-clonic seizures in H1 2027. Development of a long-acting injectable formulation and a Phase 2 bipolar mania trial remain on track with key data expected in 2027.
4. Strategic Collaboration in Greater China
Rapport entered a strategic collaboration and license agreement with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications including focal onset seizures and bipolar mania, expanding its global development footprint.